biomedics

Between the 11th and 13th of March, Barcelona will host the spring meeting of Bio-Europe, the continent’s largest partnering conference of the global biotechnology industry, for the second time. 1,300 biomedical companies will participate in the event, with more than 2,000 delegates and executives. 60 out of the 100 Spanish companies attending are from Catalonia. In the last decade, Catalonia, particularly the Greater Barcelona area, has become the most important centre in Southern Europe within the biomedical field and one of the main centres internationally. Barcelona’s Deputy Mayor for Economic Affairs, Sònia Recasens, praised the importance of the event as it boosts those “added-value sectors that are strategic for the city’s economic growth”.

The company, which is based in Greater Barcelona, is the world’s third leader in blood derivatives pharmaceutical products. Last year, it bought out its main competitor in the United States, Talecris. Grífols had a €2.62 billion turnover in 2012 and almost doubled its sales compared to the 2011 figures. The company’s net profit last year quadruples that of 2011. The good results are due to a significant reduction in debt levels and Grífols’ penetration into the United States market. Besides, this week it announced it bought for €37 million the 60% of Progenika Biopharma’s capital, a Basque biotechnology company specialised in the design of diagnostic tests.

The Catalan Institute of Oncology (ICO) has introduced a world pioneering technique which allows four out of five patients who cannot undergo surgery to survive the illness. This technique causes less after-effects than the traditional radiotherapy. Furthermore, statistics show that with the regular treatment, two thirds of these patients die. However, Ferran Gadea, the Head of the Radiotherapy and Oncology Service, says that the best option to cure a lung cancer is still to undergo the operation when possible.

This is a real stride for the cancer research. The effects of a protein called condensing on colorectal cancer have been found out by a team of Molecular Biology and Biochemistry experts, at the Research Centre for Nanomedicine (CIBBIN-Nanomedicine) at the Vall d'Hebon Research Institute. The researchers have discovered that condensin helps the tumor cells to divide rapidly, so its inhibition leads to the death of tumour cells. The results of this research were published in the 'Journal of Biology and Chemistry', and they constitute a real hope for the fight against colorectal cancer.

The technique started in Catalonia in 2007 and by 2011 it was practiced on 40% of patients with renal failure. The Catalan Health Ministry hopes to cover 100% of the cases within the next 5 to 10 years. In the United States it started being used a year ago as they were waiting for clinical results to expand its use. Now, a clinical study on 900 patients from 27 different Catalan centres has proved that the technique reduces mortality by 30% on patients with kidney failure within the first three years. In addition, it improves quality of life, reduces hospitalisations by 22% and it also makes hypotension episodes drop by 28%.

Researchers from the Universitat Autònoma de Barcelona (UAB) have managed to completely cure dogs with type 1 diabetes through a single session of gene therapy. It is the first time ever that the effectiveness of a treatment against this illness in large animals has been proved in the world. This achievement opens the door to being able to translate a similar therapy to humans and cure type 1 diabetes, which currently has no cure and means that patients have to control their blood insulin levels for their whole lives through hormone injections, as untreated it can be fatal. Diabetes mellitus type 1 is an autoimmune illness that destroys the cells of the pancreas that produce insulin, an essential hormone in the process of transforming glucose into energy for the body’s cells.

Through its FET-Flagship programme, the European Commission is allocating €1 billion to each of the two main research projects in Europe. The first one is a project to explore the properties of graphene, a new material deriving from graphite that might revolutionise industry as silicon did a few decades ago. The second one will simulate a human brain in order to understand how it exactly works. The Catalan Institute of Nanotechnology is one of the nine leading institutes coordinating the graphene project, in which 623 research groups from 32 different countries will participate. Furthermore, the Barcelona Supercomputing Center will take care of the calculations at a molecular level in the Human Brain Project.

According to experiments tested on mice, Catalan scientists have affirmed that the stem cells located in the human umbilical chord, which are multipotential and therefore can become different types of cells, can be used to regenerate the tissue affected by a heart attack or a stroke. Until now the only way to recover the damaged tissue was through pharmacological treatment or a heart transplant.

A research group led by Catalan doctor Joaquim Bellmunt at the Hospital del Mar has shown in a study how important the time between two chemotherapy treatments is in increasing the curing rates of bladder cancer. The study was published by the journal ‘European Urology’ and has encouraged the researchers to develop new drugs for treating this type of tumour.

An international study with the participation of the Hospital Clínic IDIBAPS, which is a leading research centre at a world level on AIDS/HIV and other common diseases, has proved that an anti-retroviral treatment carried out just after the infection delays the damage to the patient’s immune system and reduces the risk of transmission. The results of clinical tests on 366 infected individuals confirmed that the sooner and longer an initial anti-retroviral treatment is applied, the later the life-long treatments have to start. However, despite the results, researchers insist that is still too soon to change the current AIDS/HIV treatment protocols.

The IDIBAPS has opened a new research centre of more than 5,000 m2, where more than 200 researchers split into 23 different research groups will be working. It will focus its work on oncology, neurosciences and cell therapies along with infectious, respiratory, cardiovascular and renal diseases. The new centre has been possible thanks to a donation by the private foundation CELLEX, sponsored by Pere Mir. The new centre is located within the University of Barcelona’s Faculty of Medicine, which is integrated into the prestigious Hospital Clínic. The centre consolidates Catalonia, and in particular Barcelona, as one of Europe’s main biomedical poles.

The Barcelona-based Vall d’Hebron Research Institute (VHIR) has identified two proteins that block the metastasis of rhabdomyosarcoma, a type of cancer that represents 8% of this sort of illness in children. These two proteins are related to cellular proliferation and growth as well as having the capacity to migrate to other organs. The study opens the door to the development of new treatments targeting these two proteins. The study was funded by the foundation of the Catalan Public TV Broadcaster and it has been published in the British Journal of Cancer (BJC).

Scientists from the Colorectal Cancer Laboratory at the Barcelona Institute of Biomedical Research (IRB) have discovered the essential process that allows colon cancer cells to metastasise. They have concluded that tumour cells need to form alliances with healthy cells in order to be able to colonise other organs. Tumour cells can survive in the transition period during the metastasis process thanks to a protein (interleukin-11), which is produced by healthy cells that are exposed to another protein (TGF-beta) present in the tumour’s microenvironment. This discovery may lead to new treatments and diagnostic proceedings for colon cancer patients. A test to predict relapse cases and target treatments is likely to be ready in 5 years. The study has been published by the prestigious journal Cancer Cell.

For the first time in the world, Barcelona’s Vall d’Hebron Hospital removes two tumours through the body’s natural holes without the support of laparoscopy. This technique allows the patient to recover much quicker, since there are no external wounds to cicatrise. They have successfully removed a colon tumour and a stomach one, from two different patients who had recovered without complications.

A study developed by researchers from Barcelona’s Center of Regenerative Medicine and California’s Gene Expression Laboratory of the Salk Institute identified a mutation in the nucleus of human neural stem cells that is linked to Parkinson’s, which may help to diagnose the disease and open a new field for targeted treatments. The prestigious journal ‘Nature’ published the study, which could also help to explain why the Parkinson’s disease is often associated with clinical depression and anxiety. The Center of Regenerative Medicine in Barcelona is directed by Juan Carlos Izpisúa, who participated in the study; it is located in the Barcelona Biomedical Research Park, next to the Hospital del Mar.